HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 10:05 a.m. Eastern Time.
A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST®, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.
Every Second Counts! ®
Kiniksa Investor and Media Contact |
COCONUT GROVE, Fla., April 28, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or…
NEW YORK, April 28, 2025 /PRNewswire/ -- Muse Health is proud to announce its new…
Reality Star Joan Vassos, "Star Trek" Team, Days of our Lives' Martha Madison & Cast Members…
A new report from global research and advisory firm Info-Tech Research Group highlights the top…
In a new SHIN-NY collaboration, Hixny has made it easy for providers across the stateto screen patients for HRSN and query the state's controlled substance database. ALBANY, N.Y., April 28, 2025 /PRNewswire/ -- Hixny,…
PACS fuels faster, more precise diagnosis and patient triaging for busy healthcare providers to assist…